RegeneRx Biopharmaceuticals, Inc.
RGRX · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $77 | $77 | $77 | $77 |
| % Growth | 0% | 0% | -0% | – |
| Cost of Goods Sold | $0 | $7 | $5 | $0 |
| Gross Profit | $77 | $70 | $72 | $77 |
| % Margin | 100% | 91.4% | 93.6% | 99.9% |
| R&D Expenses | $0 | $7 | $5 | $65 |
| G&A Expenses | $1,419 | $1,399 | $1,366 | $1,274 |
| SG&A Expenses | $1,479 | $1,399 | $1,366 | $1,274 |
| Sales & Mktg Exp. | $60 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | $0 | -$0 |
| Operating Expenses | $1,479 | $1,405 | $1,371 | $1,339 |
| Operating Income | -$1,402 | -$1,329 | -$1,295 | -$1,262 |
| % Margin | -1,826.4% | -1,731.3% | -1,687.1% | -1,644% |
| Other Income/Exp. Net | -$325 | -$269 | -$229 | -$142 |
| Pre-Tax Income | -$1,727 | -$1,598 | -$1,523 | -$1,404 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,727 | -$1,598 | -$1,523 | -$1,404 |
| % Margin | -2,249.8% | -2,081.8% | -1,984.1% | -1,829% |
| EPS | -1 | -0.014 | -0.013 | -0.012 |
| % Growth | -7,094.2% | -6.1% | -10.1% | – |
| EPS Diluted | -1 | -0.014 | -0.013 | -0.012 |
| Weighted Avg Shares Out | 143,550 | 138,593 | 133,357 | 130,971 |
| Weighted Avg Shares Out Dil | 143,550 | 138,593 | 133,357 | 130,971 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $4 | $11 |
| Interest Expense | $326 | $325 | $233 | $153 |
| Depreciation & Amortization | $0 | $1,329 | $1 | $1 |
| EBITDA | -$1,402 | $56 | -$1,290 | -$1,249 |
| % Margin | -1,826.2% | 73% | -1,680% | -1,627.1% |